Galectin‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes. Issue 2 (15th November 2018)

• Record Type: Journal Article
• Authors: Tan, Kathryn C.B.; Cheung, Ching‐Lung; Lee, Alan C.H.; Lam, Joanne K.Y.; Wong, Ying; Shiu, Sammy W.M.
• Is Part Of: Diabetes/metabolism research and reviews. Volume 35:Issue 2(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-11-15
• Subjects: all‐cause mortality -- cardiovascular outcome -- galectin‐3 -- type 2 diabetes; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.642
• DOI: 10.1002/dmrr.3093
• Languages: English
• ISSNs: 1520-7552

Abstract

Abstract: Aims: Recent clinical studies have shown that galectin‐3 is a prognostic indicator in patients with coronary heart disease and in patients with heart failure. Experimental data suggest that galectin‐3 may play a role in atherogenesis. We have evaluated whether serum galectin‐3 level is associated with cardiovascular outcome in type 2 diabetes. Materials and methods: Galectin‐3 was measured in baseline samples in 1495 persons with type 2 diabetes. The primary cardiovascular outcome, incident cardiovascular events, was defined as first non‐fatal myocardial infarction, non‐fatal stroke, coronary revascularization, or death from cardiovascular cause. The secondary outcome was all‐cause mortality. Results: At baseline, 12% of the subjects had prevalent cardiovascular disease. Serum galectin‐3 was increased in the group with incident cardiovascular events compared with those who remained free of events during follow up (9.03 ± 2.98 ng/mL vs 8.15 ± 2.76, P < 0.01). Serum galectin‐3 was also significantly increased in those subjects with a fatal outcome. The hazard ratios (HR) for cardiovascular events and all‐cause mortality for individuals in the top quartile were 2.50 (95% CI 1.87, 3.36, P < 0.001) and 3.92 (95%CI 2.55, 6.01, P < 0.001), respectively. In a multivariate Cox regression analysis including traditional risk factors, log (eGFR), baseline albuminuria, and cardiovascular disease status, the HR per standard deviation change in galectin‐3 was 1.13 (95% CI 1.02, 1.26, P = 0.02) for cardiovascular events and 1.17 (95% CI 1.01, 1.35, P = 0.04) for all‐cause mortality. Conclusions: Serum galectin‐3 is associated with adverse cardiovascular outcomes in persons with type 2 diabetes independent of traditional risk factors.